OIS@ASRS

Ora’s Shapiro on the Pursuit of Retina’s “Holy Grail”

By Mario Admin | August 30, 2016

Aron Shapiro, vice president at Ora Inc., gives a comprehensive overview of the challenges and opportunities of retina therapies. Shapiro discusses Ora’s early work with…

Read More

History of Intraoperative OCT

By Mario Admin | August 30, 2016

Pars plana vitrectomy is almost a half-century old, and the earliest probes were powered by batteries, said Cynthia A. Toth, MD, the Joseph A.C. Wadsworth…

Read More

Apellis Eyeing 2017 Release of Phase II Results

By Mario Admin | August 30, 2016

Cedric Francois, CEO, Apellis Pharmaceuticals, hopes to deliver positive results to the company’s Phase II clinical trials of APL-2, a peptide targeting the C3 inhibitor…

Read More

Graybug Could File GB-102 IND Next Year

By Mario Admin | August 30, 2016

Jeffrey Cleland, president and CEO, Graybug Vision, delivered an update on its two treatments for wet age-related macular degeneration (Wet AMD) and glaucoma. The company…

Read More

Catalyst Trying to Improve Drugs by Lowering Doses

By Mario Admin | August 30, 2016

Edwin Madison, PhD, chief scientific officer, Catalyst Biosciences, says the company is developing protease therapeutic agents that work via a catalytic rather than a stoichiometric…

Read More

TMi Raising Money to Convert Destructive Macrophage

By Mario Admin | August 30, 2016

Shelley Boyd, MD, president and CSO, Translatum Medicus Inc. (TMi), reports the company has started raising capital to initiate preclinical studies – and possibly Phase…

Read More

Seeking Answers on How to Pay for Innovation in Biopharma

By Mario Admin | August 30, 2016

If cost was no consideration, retina specialists would first chose Eylea for their own anti-VEGF therapy, according to an American Society of Retina Specialists survey,…

Read More

Alimera Sciences: Addressing DME with Persistent Microdose Therapy

By Mario Admin | August 29, 2016

Alimera Sciences is focused on the commercialization of ILUVIEN (fluocinolone acetonide intravitreal implant) for diabetic macular edema (DME), which received FDA approval in 2014. The…

Read More

Aerie: Moving Beyond Glaucoma

By Mario Admin | August 29, 2016

Most ophthalmologists are aware that Aerie Pharmaceuticals is developing Rho-kinase and norepinephrine transporter inhibitors (Rhopressa, or netarsudil) for the treatment of glaucoma, and that the…

Read More

Ocular Therapeutix: Intravitreal Depot Technology for Retinal Drug Delivery

By Mario Admin | August 29, 2016

Ocular Therapeutix has built a portfolio of products around its proprietary hydrogel technology. ReSure Sealant is FDA approved for sealing clear corneal incisions following cataract…

Read More

Bioptigen Driving Intrasurgical OCT Use

By Mario Admin | August 29, 2016

Intrasurgical optical coherence tomography (OCT) is “going to make a dramatic impact on our patients’ lives,” said Eric Buckland, founder and CEO of Bioptigen, which…

Read More

TrueVision Adds Alcon as Digital Microscope Partner

By Mario Admin | August 29, 2016

TrueVision Systems’ 3D Digital Microscope Platform recently received a boost thanks to a partnership agreement with Alcon penned just before OIS@ASRS, TrueVision CEO Forrest Fleming…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.